rigel pharmaceuticals, inc., is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases.
Company profile
Ticker
RIGL
Exchange
Website
CEO
Raul Rodriguez
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
IRS number
943248524
RIGL stock data
Latest filings (excl ownership)
8-K
Entry into a Material Definitive Agreement
12 Apr 24
ARS
2023 FY
Annual report to shareholders
10 Apr 24
DEFA14A
Additional proxy soliciting materials
10 Apr 24
DEF 14A
Definitive proxy
10 Apr 24
PRE 14A
Preliminary proxy
29 Mar 24
8-K
Rigel Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
5 Mar 24
10-K
2023 FY
Annual report
5 Mar 24
8-K
Entry into a Material Definitive Agreement
22 Feb 24
8-K
Rigel Pharmaceuticals Provides Business Update
8 Jan 24
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
30 Nov 23
Transcripts
RIGL
Earnings call transcript
2023 Q4
5 Mar 24
RIGL
Earnings call transcript
2023 Q3
7 Nov 23
RIGL
Earnings call transcript
2023 Q2
1 Aug 23
RIGL
Earnings call transcript
2023 Q1
2 May 23
RIGL
Earnings call transcript
2022 Q4
7 Mar 23
RIGL
Earnings call transcript
2022 Q3
3 Nov 22
RIGL
Earnings call transcript
2022 Q2
3 Aug 22
RIGL
Earnings call transcript
2022 Q1
4 May 22
RIGL
Earnings call transcript
2021 Q4
2 Mar 22
RIGL
Earnings call transcript
2021 Q3
3 Nov 21
Latest ownership filings
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 45.41 mm | 45.41 mm | 45.41 mm | 45.41 mm | 45.41 mm | 45.41 mm |
Cash burn (monthly) | 1.13 mm | (no burn) | 1.49 mm | 1.70 mm | 453.00 k | 1.78 mm |
Cash used (since last report) | 7.77 mm | n/a | 10.21 mm | 11.65 mm | 3.11 mm | 12.24 mm |
Cash remaining | 37.65 mm | n/a | 35.21 mm | 33.77 mm | 42.31 mm | 33.18 mm |
Runway (months of cash) | 33.2 | n/a | 23.7 | 19.9 | 93.4 | 18.6 |
Institutional ownership, Q3 2023
66.4% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 109 |
Opened positions | 7 |
Closed positions | 18 |
Increased positions | 34 |
Reduced positions | 34 |
13F shares | Current |
---|---|
Total value | 114.40 bn |
Total shares | 116.51 mm |
Total puts | 60.24 k |
Total calls | 548.20 k |
Total put/call ratio | 0.1 |
Largest owners | Shares | Value |
---|---|---|
Armistice Capital | 17.14 mm | $18.51 bn |
Soleus Capital Management | 14.80 mm | $15.99 bn |
BLK Blackrock | 14.41 mm | $15.57 bn |
Soleus Capital Master Fund | 9.22 mm | $14.67 mm |
Vanguard | 8.87 mm | $9.58 bn |
MS Morgan Stanley | 6.98 mm | $7.54 bn |
Acadian Asset Management | 4.66 mm | $5.00 bn |
Geode Capital Management | 3.55 mm | $3.83 bn |
STT State Street | 3.50 mm | $3.78 bn |
Jacobs Levy Equity Management | 3.37 mm | $3.64 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
27 Mar 24 | Lisa Rojkjaer | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 1.49 | 187,500 | 279.38 k | 187,500 |
28 Feb 24 | Dean L Schorno | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 1.27 | 78,500 | 99.70 k | 78,500 |
28 Feb 24 | Dean L Schorno | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 1.87 | 62,500 | 116.88 k | 62,500 |
28 Feb 24 | David A Santos | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 1.27 | 78,500 | 99.70 k | 78,500 |
28 Feb 24 | David A Santos | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 1.87 | 80,000 | 149.60 k | 80,000 |
28 Feb 24 | Raul R Rodriguez | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 1.27 | 300,000 | 381.00 k | 300,000 |
28 Feb 24 | Raul R Rodriguez | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 1.87 | 300,000 | 561.00 k | 300,000 |
News
Rigel Publishes Data On REZLIDHIA In Post-Venetoclax Patients With Mutant IDH1 AML In Leukemia & Lymphoma
4 Apr 24
Citigroup Maintains Buy on Rigel Pharmaceuticals, Raises Price Target to $4
7 Mar 24
Cantor Fitzgerald Maintains Neutral on Rigel Pharmaceuticals, Raises Price Target to $3
6 Mar 24
HC Wainwright & Co. Reiterates Buy on Rigel Pharmaceuticals, Maintains $15 Price Target
6 Mar 24
B. Riley Securities Maintains Neutral on Rigel Pharmaceuticals, Maintains $1.25 Price Target
6 Mar 24
Press releases
Rigel Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
10 Apr 24
Rigel Announces Publication of Data on REZLIDHIA® (Olutasidenib) in Post-Venetoclax Patients with Mutant IDH1 AML in Leukemia & Lymphoma
4 Apr 24
Rigel Announces Publication of Data on REZLIDHIA® (Olutasidenib) in Post-Venetoclax Patients with Mutant IDH1 AML in Leukemia & Lymphoma
4 Apr 24
Rigel Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
5 Mar 24
Recent Market Movers: Healthcare Companies Making Headlines: DYAI, RIGL, ARDX, VERO, MEDS
28 Feb 24